Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MPB Cologne GMBH

This article was originally published in Start Up

Executive Summary

MPB Cologne is working to turn transgenic potato tubers into a raw-materials production system for antibodies and other proteins. The company hopes partners will provide it with genes for proteins that MPB will produce, extract and purify, then return to partners for end-product development and commercialization. Management thinks its potatoes will be environmentally safer systems than pollinated plants, especially if the firm succeeds in developing a system whereby proteins will be produced in the tubers only after they are harvested and put into oxygen-deprived containers. A pilot-scale field trial is scheduled this year in Canada.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel